A Rare Case of Rhabdoid Pancreatic Carcinoma: Prolonged Disease-Free Survival Following Upfront Resection and Adjuvant Chemotherapy DOI Open Access

Gabriel Land,

Benjamin Van Haeringen, Caroline Cooper

et al.

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Dec. 7, 2023

The rhabdoid subtype of undifferentiated pancreatic carcinoma is rarely reported. clinical course this disease therefore poorly understood, although it apparently an aggressive malignancy. We herein discuss the case a 69-year-old man presenting with rapidly enlarging mass body and tail who was diagnosed locally advanced SMARCB1-deficient features, treated radical resection adjuvant chemotherapy, has achieved 18-month disease-free survival ongoing at time article publication. identify contrast our 15 similar tumors reported in English literature, briefly biology tumor, its relationship to malignant childhood, role SMARCB1 parent complex switch/sucrose-non-fermentable chromatin remodeling (SWI/SNF) modulating behavior malignancy, potential therapeutic avenues available for SWI/SNF-mutated malignancies.

Language: Английский

Molecular Mapping in Head and Neck Adenoid Cystic Carcinoma by Pathological Grade Using Whole-exome Sequencing and Spatial Transcriptome DOI

Yuelu Zhu,

Li Lin, Shun Wang

et al.

Human Pathology, Journal Year: 2025, Volume and Issue: unknown, P. 105758 - 105758

Published: March 1, 2025

Language: Английский

Citations

0
Identification of TEFM as a potential therapeutic target for LUAD treatment DOI Creative Commons

Wenxuan Hu,

Jian Yang, Kang Hu

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: July 29, 2024

Abstract Background Molecularly targeted therapies have recently become a hotspot in the treatment of LUAD, with ongoing efforts to identify new effective targets due individual variability. Among these potential targets, mitochondrial transcription elongation factor (TEFM) stands out as crucial molecule involved synthetic transcriptional processing. Dysregulation TEFM has been implicated development various diseases; however, its specific role LUAD remains unclear. Methods We conducted comprehensive analysis expression leveraging data from TCGA database. Subsequently, we validated findings using clinical specimens obtained First Affiliated Hospital Soochow University, employing western blotting and qRT-PCR techniques. Further experimental validation was performed through transfection cells overexpression, knockdown, knockout lentiviruses. The effects on were evaluated both vitro vivo range assays, including CCK-8, colony formation, EdU incorporation, Transwell migration, Tunel assay, flow cytometry, JC-1 staining, xenograft tumour models. Results Our investigation uncovered that exhibited elevated levels co-localization mitochondria. Overexpression facilitated malignant processes cells, whereas silencing notably curbed behaviors induced depolarization, along ROS production, culminating apoptosis. Moreover, absence substantially influenced transcripts respiratory chain complexes. nude mouse tumors further inhibiting markedly hindered tumor growth. Conclusion promotes progression EMT pathway determines apoptosis by affecting complexes, providing therapeutic direction for LUAD-targeted therapy. Graphical

Language: Английский

Citations

1
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes DOI Open Access
Yue Ma, Natisha Field, Tao Xie

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 3068 - 3068

Published: Sept. 3, 2024

SWI/SNF (SWItch/Sucrose Non-Fermentable) is the most frequently mutated chromatin-remodelling complex in human malignancy, with over 20% of tumours having a mutation member. Mutations specific members are characteristic rare chemoresistant ovarian cancer histopathological subtypes. Somatic mutations

Language: Английский

Citations

1
Foxd3/SLC5A6 axis regulates apoptosis in LUAD cells by controlling mitochondrial biotin uptake DOI
Chong Zheng,

Wenxuan Hu,

Danni Wu

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 125, P. 111473 - 111473

Published: Oct. 18, 2024

Language: Английский

Citations

0
SWItch/Sucrose Nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy DOI Open Access
Yu Gu,

Songtao Lai,

Juan Yang

et al.

Translational Lung Cancer Research, Journal Year: 2024, Volume and Issue: 13(10), P. 2660 - 2672

Published: Oct. 1, 2024

The SWItch/Sucrose Nonfermentable (SWI/SNF) complex, a multi-subunit chromatin remodeler, is linked to aggressive tumors when deficient. Accurate identification of SWI/SNF expression status crucial for tailoring targeted therapies. Previous studies on the efficacy immunotherapy SWI/SNF-deficient (SWI/SNF-d) pulmonary primarily focus non-small cell lung cancer (NSCLC), with limited data other modalities like radiotherapy. This study aims analyze clinicopathological characteristics and prognostic factors SWI/SNF-d neoplasms, including NSCLC undifferentiated tumors, evaluate effectiveness radiotherapy immunotherapy, providing foundation improved treatment strategies assessments.

Language: Английский

Citations

0
ARID2 Deficiency Enhances Tumor Progression via ERBB3 Signaling in TFE3-Rearranged Renal Cell Carcinoma DOI Creative Commons
Jinglong Tang,

Shintaro Funasaki,

Hidekazu Nishizawa

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(12), P. 13675 - 13695

Published: Dec. 2, 2024

TFE3-rearranged Renal Cell Carcinoma (TFE3-RCC) is an aggressive subtype of RCC characterized by Xp11.2 rearrangement, leading to TFE3 fusion proteins with oncogenic potential. Despite advances in understanding its molecular biology, effective therapies for advanced cases remain elusive. This study investigates the role ARID2, a component SWI/SNF chromatin remodeling complex, TFE3-RCC. Through series vitro and vivo experiments, we confirmed that ARID2 acts as tumor suppressor knockout (KO) enhanced TFE3-RCC cell migration, proliferation, growth. Transcriptomic analysis revealed ERBB3 key target gene regulated both PRCC-TFE3 ARID2. Chromatin immunoprecipitation (ChIP) assays demonstrated directly binds upregulates expression, KO further enhancing this effect. cells exhibited significant expression enrichment MAPK signaling pathways. These also showed increased activation ERBB3, EGFR, selective SRC MAPK. heightened sensitivity inhibitor AZD8931 compared their wild-type counterparts, exhibiting significantly reduced migration proliferation rates. findings suggest PRCC-TFE3-ARID2-ERBB3 axis plays critical pathogenesis highlights potential targeting ARID2-deficient therapeutic strategy. provides new insights into mechanisms suggests avenues precision treatment cancer.

Language: Английский

Citations

0
A Rare Case of Rhabdoid Pancreatic Carcinoma: Prolonged Disease-Free Survival Following Upfront Resection and Adjuvant Chemotherapy DOI Open Access

Gabriel Land,

Benjamin Van Haeringen, Caroline Cooper

et al.

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Dec. 7, 2023

The rhabdoid subtype of undifferentiated pancreatic carcinoma is rarely reported. clinical course this disease therefore poorly understood, although it apparently an aggressive malignancy. We herein discuss the case a 69-year-old man presenting with rapidly enlarging mass body and tail who was diagnosed locally advanced SMARCB1-deficient features, treated radical resection adjuvant chemotherapy, has achieved 18-month disease-free survival ongoing at time article publication. identify contrast our 15 similar tumors reported in English literature, briefly biology tumor, its relationship to malignant childhood, role SMARCB1 parent complex switch/sucrose-non-fermentable chromatin remodeling (SWI/SNF) modulating behavior malignancy, potential therapeutic avenues available for SWI/SNF-mutated malignancies.

Language: Английский

Citations

0